407 related articles for article (PubMed ID: 20038811)
1. BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination.
Derré L; Rivals JP; Jandus C; Pastor S; Rimoldi D; Romero P; Michielin O; Olive D; Speiser DE
J Clin Invest; 2010 Jan; 120(1):157-67. PubMed ID: 20038811
[TBL] [Abstract][Full Text] [Related]
2. B and T lymphocyte attenuator mediates inhibition of tumor-reactive CD8+ T cells in patients after allogeneic stem cell transplantation.
Hobo W; Norde WJ; Schaap N; Fredrix H; Maas F; Schellens K; Falkenburg JH; Korman AJ; Olive D; van der Voort R; Dolstra H
J Immunol; 2012 Jul; 189(1):39-49. PubMed ID: 22634623
[TBL] [Abstract][Full Text] [Related]
3. Putting the brakes on BTLA in T cell-mediated cancer immunotherapy.
Paulos CM; June CH
J Clin Invest; 2010 Jan; 120(1):76-80. PubMed ID: 20038807
[TBL] [Abstract][Full Text] [Related]
4. CpG-ODN-induced sustained expression of BTLA mediating selective inhibition of human B cells.
Thibult ML; Rivals JP; Mamessier E; Gertner-Dardenne J; Pastor S; Speiser DE; Derré L; Olive D
J Mol Med (Berl); 2013 Feb; 91(2):195-205. PubMed ID: 22903545
[TBL] [Abstract][Full Text] [Related]
5. B and T lymphocyte attenuator is highly expressed on CMV-specific T cells during infection and regulates their function.
Serriari NE; Gondois-Rey F; Guillaume Y; Remmerswaal EB; Pastor S; Messal N; Truneh A; Hirsch I; van Lier RA; Olive D
J Immunol; 2010 Sep; 185(6):3140-8. PubMed ID: 20693422
[TBL] [Abstract][Full Text] [Related]
6. Differential effects of B and T lymphocyte attenuator and programmed death-1 on acceptance of partially versus fully MHC-mismatched cardiac allografts.
Tao R; Wang L; Han R; Wang T; Ye Q; Honjo T; Murphy TL; Murphy KM; Hancock WW
J Immunol; 2005 Nov; 175(9):5774-82. PubMed ID: 16237069
[TBL] [Abstract][Full Text] [Related]
7. Multifaceted Role of BTLA in the Control of CD8
Ritthipichai K; Haymaker CL; Martinez M; Aschenbrenner A; Yi X; Zhang M; Kale C; Vence LM; Roszik J; Hailemichael Y; Overwijk WW; Varadarajan N; Nurieva R; Radvanyi LG; Hwu P; Bernatchez C
Clin Cancer Res; 2017 Oct; 23(20):6151-6164. PubMed ID: 28754817
[No Abstract] [Full Text] [Related]
8. CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1.
Fourcade J; Sun Z; Pagliano O; Guillaume P; Luescher IF; Sander C; Kirkwood JM; Olive D; Kuchroo V; Zarour HM
Cancer Res; 2012 Feb; 72(4):887-96. PubMed ID: 22205715
[TBL] [Abstract][Full Text] [Related]
9. TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients.
Chauvin JM; Pagliano O; Fourcade J; Sun Z; Wang H; Sander C; Kirkwood JM; Chen TH; Maurer M; Korman AJ; Zarour HM
J Clin Invest; 2015 May; 125(5):2046-58. PubMed ID: 25866972
[TBL] [Abstract][Full Text] [Related]
10. Distinct expression and inhibitory function of B and T lymphocyte attenuator on human T cells.
Wang XF; Chen YJ; Wang Q; Ge Y; Dai Q; Yang KF; Fang-Xie ; Zhou YH; Hu YM; Mao YX; Zhang XG
Tissue Antigens; 2007 Feb; 69(2):145-53. PubMed ID: 17257317
[TBL] [Abstract][Full Text] [Related]
11. BTLA interaction with HVEM expressed on CD8(+) T cells promotes survival and memory generation in response to a bacterial infection.
Steinberg MW; Huang Y; Wang-Zhu Y; Ware CF; Cheroutre H; Kronenberg M
PLoS One; 2013; 8(10):e77992. PubMed ID: 24205057
[TBL] [Abstract][Full Text] [Related]
12. Peptide-specific CD8+ T-cell evolution in vivo: response to peptide vaccination with Melan-A/MART-1.
Jäger E; Höhn H; Necker A; Förster R; Karbach J; Freitag K; Neukirch C; Castelli C; Salter RD; Knuth A; Maeurer MJ
Int J Cancer; 2002 Mar; 98(3):376-88. PubMed ID: 11920589
[TBL] [Abstract][Full Text] [Related]
13. Dual inhibition of BTLA and PD-1 can enhance therapeutic efficacy of paclitaxel on intraperitoneally disseminated tumors.
Sun WZ; Lin HW; Chen WY; Chien CL; Lai YL; Chen J; Chen YL; Cheng WF
J Immunother Cancer; 2023 Jul; 11(7):. PubMed ID: 37463789
[TBL] [Abstract][Full Text] [Related]
14. BTLA-HVEM Checkpoint Axis Regulates Hepatic Homeostasis and Inflammation in a ConA-Induced Hepatitis Model in Zebrafish.
Shi W; Shao T; Li JY; Fan DD; Lin AF; Xiang LX; Shao JZ
J Immunol; 2019 Nov; 203(9):2425-2442. PubMed ID: 31562209
[TBL] [Abstract][Full Text] [Related]
15. PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients.
Fourcade J; Kudela P; Sun Z; Shen H; Land SR; Lenzner D; Guillaume P; Luescher IF; Sander C; Ferrone S; Kirkwood JM; Zarour HM
J Immunol; 2009 May; 182(9):5240-9. PubMed ID: 19380770
[TBL] [Abstract][Full Text] [Related]
16. Anti-HVEM mAb therapy improves antitumoral immunity both in vitro and in vivo, in a novel transgenic mouse model expressing human HVEM and BTLA molecules challenged with HVEM expressing tumors.
Demerlé C; Gorvel L; Mello M; Pastor S; Degos C; Zarubica A; Angelis F; Fiore F; Nunes JA; Malissen B; Greillier L; Guittard G; Luche H; Barlesi F; Olive D
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37230538
[TBL] [Abstract][Full Text] [Related]
17. BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1.
Watanabe N; Gavrieli M; Sedy JR; Yang J; Fallarino F; Loftin SK; Hurchla MA; Zimmerman N; Sim J; Zang X; Murphy TL; Russell JH; Allison JP; Murphy KM
Nat Immunol; 2003 Jul; 4(7):670-9. PubMed ID: 12796776
[TBL] [Abstract][Full Text] [Related]
18. In vivo activation of melanoma-specific CD8(+) T cells by endogenous tumor antigen and peptide vaccines. A comparison to virus-specific T cells.
Speiser DE; Liénard D; Pittet MJ; Batard P; Rimoldi D; Guillaume P; Cerottini JC; Romero P
Eur J Immunol; 2002 Mar; 32(3):731-41. PubMed ID: 11870617
[TBL] [Abstract][Full Text] [Related]
19. Distinct Changes of BTLA and HVEM Expressions in Circulating CD4
Liu J; Li J; He M; Zhang GL; Zhao Q
J Immunol Res; 2018; 2018():4561571. PubMed ID: 30116751
[TBL] [Abstract][Full Text] [Related]
20. Soluble B and T lymphocyte attenuator possesses antitumor effects and facilitates heat shock protein 70 vaccine-triggered antitumor immunity against a murine TC-1 cervical cancer model in vivo.
Han L; Wang W; Fang Y; Feng Z; Liao S; Li W; Li Y; Li C; Maitituoheti M; Dong H; Lai Z; Gao Q; Xi L; Wu M; Wang D; Zhou J; Meng L; Wang S; Ma D
J Immunol; 2009 Dec; 183(12):7842-50. PubMed ID: 19923459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
